Product
ANX005
4 clinical trials
4 indications
Indication
Warm Autoimmune Hemolytic AnemiaIndication
Amyotrophic lateral sclerosisIndication
Guillain-Barre SyndromeIndication
Huntington's diseaseClinical trial
A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Intravenous ANX005 in Subjects With Warm Autoimmune Hemolytic Anemia (wAIHA)Status: Completed, Estimated PCD: 2023-01-17
Clinical trial
A Phase 2a Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Intravenous ANX005 in Subjects With, or at Risk for, Manifest Huntington's DiseaseStatus: Completed, Estimated PCD: 2022-01-28
Clinical trial
A Phase 2a Safety, Tolerability, Pharmacokinetic (PK), and Pharmacodynamic (PD) Study of Intravenous ANX005 in Subjects With Amyotrophic Lateral Sclerosis (ALS)Status: Recruiting, Estimated PCD: 2023-10-01
Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase 3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of ANX005 in Subjects With Guillain-Barré SyndromeStatus: Recruiting, Estimated PCD: 2024-04-30